Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggard

Regeneron Pharmaceuticals ( REGN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.4%. By the end of trading, Regeneron Pharmaceuticals fell $5.93 (-2.2%) to $262.71 on light volume. Throughout the day, 723,955 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1,239,100 shares. The stock ranged in price between $258.32-$270.82 after having opened the day at $267.23 as compared to the previous trading day's close of $268.64. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 37.2%, Regulus Therapeutics ( RGLS), down 12.0%, Anika Therapeutics ( ANIK), down 10.1% and Aoxing Pharmaceutical Company ( AXN), down 9.1%.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $25.5 billion and is part of the health care sector. Shares are up 55.5% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, Aratana Therapeutics ( PETX), up 15.9%, Ventrus Biosciences ( VTUS), up 10.4%, Senesco Technologies ( SNTI), up 10.0% and Epizyme ( EPZM), up 8.5%.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.